Peter M George

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1964468/publications.pdf

Version: 2024-02-01

309	9,754	41627	56606
papers	citations	51 h-index	87 g-index

309	309	309	10761
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A prospective multi-centre study assessing the safety and effectiveness following the implementation of an accelerated chest pain pathway using point-of-care troponin for use in New Zealand rural hospital and primary care settings. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 418-427.	0.4	4
2	Implementation and evaluation of a rural general practice assessment pathway for possible cardiac chest pain using point-of-care troponin testing: a pilot study. BMJ Open, 2022, 12, e044801.	0.8	3
3	Precision diagnostics: Integration of tissue pathology and genomics in cancer. Pathology, 2021, 53, 809-817.	0.3	2
4	Early kinetic profiles of troponin I and T measured by high-sensitivity assays in patients with myocardial infarction. Clinica Chimica Acta, 2020, 505, 15-25.	0.5	28
5	Machine Learning to Predict the Likelihood of Acute Myocardial Infarction. Circulation, 2019, 140, 899-909.	1.6	128
6	Comparative aspects of the care of familial hypercholesterolemia in the â€œTen Countries Studyâ€• Journal of Clinical Lipidology, 2019, 13, 287-300.	0.6	32
7	A Risk Assessment Score and Initial Highâ€•sensitivity Troponin Combine to Identify Low Risk of Acute Myocardial Infarction in the Emergency Department. Academic Emergency Medicine, 2018, 25, 434-443.	0.8	12
8	ICare-ACS (Improving Care Processes for Patients With Suspected Acute Coronary Syndrome). Circulation, 2018, 137, 354-363.	1.6	32
9	Validity of a Novel Point-of-Care Troponin Assay for Single-Test Rule-Out of Acute Myocardial Infarction. JAMA Cardiology, 2018, 3, 1108.	3.0	60
10	Detectable High-Sensitivity Cardiac Troponin within the Population Reference Interval Conveys High 5-Year Cardiovascular Risk: An Observational Study. Clinical Chemistry, 2018, 64, 1044-1053.	1.5	33
11	Antiâ€‹<scp>HMGCR</scp> autoantibodies in selfâ€‹limiting statinâ€‹induced myopathy. International Journal of Rheumatic Diseases, 2017, 20, 2179-2181.	0.9	7
12	Rapid Rule-out of Acute Myocardial Infarction With a Single High-Sensitivity Cardiac Troponin T Measurement Below the Limit of Detection. Annals of Internal Medicine, 2017, 166, 715.	2.0	231
13	Is N,N-dimethylglycine N-oxide a choline and betaine metabolite?. Biological Chemistry, 2017, 398, 775-784.	1.2	7
14	Compound Heterozygous Inheritance of Mutations in Coenzyme Q8A Results in Autosomal Recessive Cerebellar Ataxia and Coenzyme Q10 Deficiency in a Female Sib-Pair. JIMD Reports, 2017, 42, 31-36.	0.7	21
15	Massive parallel sequencing of solid tumours â€“ challenges and opportunities for pathologists. Histopathology, 2017, 70, 123-133.	1.6	12
16	Design of the Familial Hypercholesterolaemia Australasia Network Registry: Creating Opportunities for Greater International Collaboration. Journal of Atherosclerosis and Thrombosis, 2017, 24, 1075-1084.	0.9	29
17	Translational Research for Improving the Care of Familial Hypercholesterolemia: The â€œTen Countries Studyâ€•and Beyond. Journal of Atherosclerosis and Thrombosis, 2016, 23, 891-900.	0.9	36
18	Effectiveness of EDACS Versus ADAPT Accelerated Diagnostic Pathways for Chest Pain: A Pragmatic Randomized Controlled Trial Embedded Within Practice. Annals of Emergency Medicine, 2016, 68, 93-102.e1.	0.3	107

#	Article	IF	Citations
19	Validation of presentation and 3â€…h high-sensitivity troponin to rule-in and rule-out acute myocardial infarction. Heart, 2016, 102, 1270-1278.	1.2	82
20	Sudden Cardiac Death Due to Deficiency of the Mitochondrial Inorganic Pyrophosphatase PPA2. American Journal of Human Genetics, 2016, 99, 674-682.	2.6	48
21	Assessment of the European Society of Cardiology 0-Hour/1-Hour Algorithm to Rule-Out and Rule-In Acute Myocardial Infarction. Circulation, 2016, 134, 1532-1541.	1.6	111
22	Heart Fatty Acid Binding Protein and cardiac troponin: development of an optimal rule-out strategy for acute myocardial infarction. BMC Emergency Medicine, 2016, 16, 34.	0.7	20
23	Unique albumin with two silent substitutions (540Thrâ†'Ala and 546Alaâ†'Ser): Insights into how albumin is recycled. Clinica Chimica Acta, 2016, 457, 125-129.	0.5	3
24	Familial dysalbuminaemic hyperthyroxinaemia: a rapid and novel mass spectrometry approach to diagnosis. Annals of Clinical Biochemistry, 2016, 53, 504-507.	0.8	9
25	Removal of body surface area normalisation improves rawâ€measured glomerular filtration rate estimation by the Chronic Kidney Disease Epidemiology Collaboration equation and drug dosing in the obese. Internal Medicine Journal, 2015, 45, 766-773.	0.5	21
26	Beware the dog that didn't bark: a tale of creatinine in acute kidney injury. Internal Medicine Journal, 2015, 45, 878-879.	0.5	1
27	Differential extraction of endogenous and exogenous 25-OH-vitamin D from serum makes the accurate quantification in liquid chromatography-tandem mass spectrometry assays challenging. Annals of Clinical Biochemistry, 2015, 52, 151-160.	0.8	18
28	Comparative performances of the new chronic kidney disease epidemiology equations incorporating cystatin <scp>C</scp> for use in cancer patients. Asia-Pacific Journal of Clinical Oncology, 2015, 11, 142-151.	0.7	16
29	The utility of presentation and 4-hour high sensitivity troponin I to rule-out acute myocardial infarction in the emergency department. Clinical Biochemistry, 2015, 48, 1219-1224.	0.8	11
30	Relative quantification of albumin and fibrinogen modifications by liquid chromatography tandem mass spectrometry in the diagnosis and monitoring of acute pancreatitis. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 988, 121-126.	1.2	3
31	Comparison of BD VacutainerÂ® Rapid Serum Tube and plasma for haemolysis markers in the emergency department. Annals of Clinical Biochemistry, 2015, 52, 293-296.	0.8	9
32	Variation of betaine, N,N-dimethylglycine, choline, glycerophosphorylcholine, taurine and trimethylamine-N-oxide in the plasma and urine of overweight people with type 2 diabetes over a two-year period. Annals of Clinical Biochemistry, 2015, 52, 352-360.	0.8	60
33	Betaine and Trimethylamine-N-Oxide as Predictors of Cardiovascular Outcomes Show Different Patterns in Diabetes Mellitus: An Observational Study. PLoS ONE, 2014, 9, e114969.	1.1	184
34	The clinical utility window for acute kidney injury biomarkers in the critically ill. Critical Care, 2014, 18, 601.	2.5	40
35	Falsely elevated plasma selenium due to gadolinium contrast interference: a novel solution to a preanalytical problem. Annals of Clinical Biochemistry, 2014, 51, 714-716.	0.8	4
36	Comparison of new point-of-care troponin assay with high sensitivity troponin in diagnosing myocardial infarction. International Journal of Cardiology, 2014, 177, 182-186.	0.8	30

#	Article	IF	Citations
37	Lean mass modulates glomerular filtration rate in males of normal and extreme body composition. Internal Medicine Journal, 2014, 44, 749-756.	0.5	23
38	Human Genetics Society of Australasia Position Statement: Population-Based Carrier Screening for Cystic Fibrosis. Twin Research and Human Genetics, 2014, 17, 578-583.	0.3	15
39	Laboratory Turnaround Times in Response to an Abrupt Increase in Specimen Testing After a Natural Disaster. American Journal of Clinical Pathology, 2014, 142, 35-42.	0.4	1
40	Extreme Urinary Betaine Losses in Type 2 Diabetes Combined with Bezafibrate Treatment are Associated with Losses of Dimethylglycine and Choline but not with Increased Losses of Other Osmolytes. Cardiovascular Drugs and Therapy, 2014, 28, 459-468.	1.3	14
41	Comparison of Abbott Architect high-sensitivity troponin I in Rapid Serum Tubes and plasma. Clinical Chemistry and Laboratory Medicine, 2014, 53, e1-3.	1.4	1
42	Fenofibrate causes elevation of betaine excretion but not excretion of other osmolytes by healthyÂadults. Journal of Clinical Lipidology, 2014, 8, 433-440.	0.6	9
43	Comparison of high sensitivity troponin T and I assays in the diagnosis of non-ST elevation acute myocardial infarction in emergency patients with chest pain. Clinical Biochemistry, 2014, 47, 321-326.	0.8	32
44	A 2-Hour Diagnostic Protocol for Possible Cardiac Chest Pain in the Emergency Department. JAMA Internal Medicine, 2014, 174, 51.	2.6	151
45	Comparison of cardiac TnI outliers using a contemporary and a high-sensitivity assay on the Abbott Architect platform. Annals of Clinical Biochemistry, 2014, 51, 507-511.	0.8	16
46	Genetic Polymorphism rs6922269 in the MTHFD1L Gene Is Associated with Survival and Baseline Active Vitamin B12 Levels in Post-Acute Coronary Syndromes Patients. PLoS ONE, 2014, 9, e89029.	1.1	12
47	The relative effects of fat versus muscle mass on cystatin C and estimates of renal function in healthy young men. Annals of Clinical Biochemistry, 2013, 50, 39-46.	0.8	64
48	Validation of High-Sensitivity Troponin I in a 2-Hour Diagnostic Strategy to Assess 30-Day Outcomes in Emergency Department Patients With Possible AcuteÂCoronary Syndrome. Journal of the American College of Cardiology, 2013, 62, 1242-1249.	1.2	277
49	Trilateral Retinoblastoma in a Patient With Peutzâ€“<scp>J</scp>eghers Syndrome. American Journal of Medical Genetics, Part A, 2013, 161, 1096-1100.	0.7	4
50	Validation of the Vancouver Chest Pain Rule using troponin as the only biomarker: a prospective cohort study. American Journal of Emergency Medicine, 2013, 31, 1103-1107.	0.7	9
51	Functional rescue of mutant ABCA1 proteins by sodium 4-phenylbutyrate. Journal of Lipid Research, 2013, 54, 55-62.	2.0	27
52	A Randomized, Double-Blind, Placebo-Controlled Crossover Study of Coenzyme Q10 Therapy in Hypertensive Patients With the Metabolic Syndrome. American Journal of Hypertension, 2012, 25, 261-270.	1.0	53
53	Plasma betaine concentrations correlate with plasma cortisol but not with C-reactive protein in an elderly population. Clinical Chemistry and Laboratory Medicine, 2012, 50, .	1.4	4
54	Betaine excretion correlates with plasma homocysteine when plasma lipids are elevated. Clinical Biochemistry, 2012, 45, 154-156.	0.8	6

#	Article	IF	Citations
55	A mass-spectroscopic method for measuring des-Leu albumin â€" A novel marker for chronic pancreatitis. Clinical Biochemistry, 2012, 45, 1664-1668.	0.8	13
56	Immune Reactivity of Four Monoclonal and Two Polyclonal Antibodies Raised Against Recombinant Pneumococcal Surface Adhesin A. Hybridoma, 2012, 31, 168-175.	0.5	0
57	Determination of methylphenidate and its metabolite ritalinic acid in urine by liquid chromatography/tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 881-882, 20-26.	1.2	20
58	Variability of plasma and urine betaine in diabetes mellitus and its relationship to methionine load test responses: an observational study. Cardiovascular Diabetology, 2012, 11, 34.	2.7	26
59	2-Hour Accelerated Diagnostic Protocol to Assess Patients With Chest Pain Symptoms Using Contemporary Troponins as the Only Biomarker. Journal of the American College of Cardiology, 2012, 59, 2091-2098.	1.2	361
60	A New Model of Care for Familial Hypercholesterolaemia: What is the Role of Cardiology?. Heart Lung and Circulation, 2012, 21, 543-550.	0.2	16
61	The Contrasting Relationships between Betaine and Homocysteine in Two Clinical Cohorts are Associated with Plasma Lipids and Drug Treatments. PLoS ONE, 2012, 7, e32460.	1.1	3
62	Betaine and Secondary Events in an Acute Coronary Syndrome Cohort. PLoS ONE, 2012, 7, e37883.	1.1	59
63	Plasma betaine concentrations correlate with plasma cortisol but not with C-reactive protein in an elderly population. Clinical Chemistry and Laboratory Medicine, 2012, 50, 1635-40.	1.4	5
64	Pharmacokinetic Comparison of a Generic Coenzyme Q₁₀ Solubilizate and a Formulation with Soybean Phytosterols. Phytotherapy Research, 2012, 26, 1092-1096.	2.8	3
65	Using the experiences of people with familial hypercholesterolaemia to help reduce the risk of cardiovascular disease: a qualitative systematic review. Journal of Advanced Nursing, 2012, 68, 1920-1932.	1.5	14
66	A model of care for familial hypercholesterolaemia: key role for clinical biochemistry. Clinical Biochemist Reviews, 2012, 33, 25-31.	3.3	13
67	High sensitivity troponin outperforms contemporary assays in predicting major adverse cardiac events up to two years in patients with chest pain. Annals of Clinical Biochemistry, 2011, 48, 249-255.	0.8	29
68	Comparison of high sensitivity and contemporary troponin assays for the early detection of acute myocardial infarction in the emergency department. Annals of Clinical Biochemistry, 2011, 48, 241-248.	0.8	60
69	Improved performance of urinary biomarkers of acute kidney injury in the critically ill by stratification for injury duration and baseline renal function. Kidney International, 2011, 79, 1119-1130.	2.6	232
70	An ABCA1 truncation shows no dominant negative effect in a familial hypoalphalipoproteinemia pedigree with three ABCA1 mutations. Biochemical and Biophysical Research Communications, 2011, 409, 400-405.	1.0	5
71	Genotyping the factor VIII intron 22 inversion locus using fluorescent in situ hybridizationâ˜†. Blood Cells, Molecules, and Diseases, 2011, 46, 151-158.	0.6	1
72	Relationship between plasma coenzyme Q10, asymmetric dimethylarginine and arterial stiffness in patients with phenotypic or genotypic familial hypercholesterolemia on long-term statin therapy. Atherosclerosis, 2011, 218, 188-193.	0.4	11

#	Article	IF	Citations
73	Familial hypercholesterolaemia: A model of care for Australasia. Atherosclerosis Supplements, 2011, 12, 221-263.	1.2	181
74	A 2-h diagnostic protocol to assess patients with chest pain symptoms in the Asia-Pacific region (ASPECT): a prospective observational validation study. Lancet, The, 2011, 377, 1077-1084.	6.3	316
75	HSP70 Antibodies in 80 Patients with â€œClinically Certainâ€•Meniere's Disease. Annals of Otology, Rhinology and Laryngology, 2011, 120, 651-655.	0.6	13
76	Vasopressin in definite Meniere's disease with positive electrocochleographic findings. Acta Oto-Laryngologica, 2011, 131, 613-617.	0.3	12
77	Four cases of autosomal dominant hypocalcaemia with hypercalciuria including two with novel mutations in the calcium-sensing receptor gene. Annals of Clinical Biochemistry, 2011, 48, 286-290.	0.8	6
78	What is the best predictor of the atherogenic LDL subclass phenotype â€˜pattern Bâ€™ in patients with type 2 diabetes mellitus?. Annals of Clinical Biochemistry, 2011, 48, 166-169.	0.8	13
79	Plasma Lipids and Betaine Are Related in an Acute Coronary Syndrome Cohort. PLoS ONE, 2011, 6, e21666.	1.1	49
80	Trimethylaminuria: causes and diagnosis of a socially distressing condition. Clinical Biochemist Reviews, 2011, 32, 33-43.	3.3	81
81	Role of genetic testing in retinoblastoma management at a tertiary referral centre. Clinical and Experimental Ophthalmology, 2010, 38, 231-236.	1.3	14
82	Preimplantation genetic diagnosis for hemophiliaÂA using indirect linkage analysis and direct genotyping approaches. Journal of Thrombosis and Haemostasis, 2010, 8, 783-789.	1.9	37
83	The Effect of Hemolysis on Current Troponin Assaysâ€”A Confounding Preanalytical Variable?. Clinical Chemistry, 2010, 56, 1195-1197.	1.5	52
84	Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 302	2.6	231
85	Plasma Sex Hormone-binding Globulin, Corticosteroid-binding Globulin, Cortisol, and Free Cortisol Levels in Outpatients Attending a Lipid Disorders Clinic: A Cross-sectional Study of 1137 Subjects. Hormone and Metabolic Research, 2010, 42, 274-279.	0.7	21
86	The prevalence of lactose intolerance (adult hypolactasia) in a randomly selected New Zealand population. New Zealand Medical Journal, 2010, 123, 123.	0.5	3
87	Fatty infiltration of the liver in a case of hypobetalipoproteinaemia with a novel mutation in the APOB gene. New Zealand Medical Journal, 2010, 123, 98-100.	0.5	1
88	Homozygous familial hypercholesterolaemia and treatment by LDL apheresis. New Zealand Medical Journal, 2010, 123, 79-82.	0.5	0
89	Fibrates plus betaine: a winning combination?. New Zealand Medical Journal, 2010, 123, 74-8.	0.5	11
90	Preventing cardiovascular disease: a review of the effectiveness of identifying the people with familial hypercholesterolaemia in New Zealand. New Zealand Medical Journal, 2010, 123, 97-102.	0.5	16

#	Article	IF	Citations
91	Demonstration of heterodimeric fibrinogen molecules partially conjugated with albumin in a novel dysfibrinogen: Fibrinogen Mannheim V. Thrombosis and Haemostasis, 2009, 102, 29-34.	1.8	10
92	Folate and vitamin B12status of women of reproductive age living in Hanoi City and Hai Duong Province of Vietnam. Public Health Nutrition, 2009, 12, 941-946.	1.1	9
93	Thiopurine methyltransferase and thiopurine metabolite testing in patients with inflammatory bowel disease who are taking thiopurine drugs. Pharmacogenomics, 2009, 10, 1091-1099.	0.6	9
94	A deep intronic mutation inFGBcreates a consensus exonic splicing enhancer motif that results in afibrinogenemia caused by aberrant mRNA splicing, which can be corrected in vitro with antisense oligonucleotide treatment. Human Mutation, 2009, 30, 221-227.	1.1	58
95	Betaine structure and the presence of hydroxyl groups alters the effects on DNA melting temperatures. Biopolymers, 2009, 91, 85-94.	1.2	19
96	Evaluation of high-resolution melting analysis for screening the LDL receptor gene. Clinical Biochemistry, 2009, 42, 528-535.	0.8	18
97	Fibrates may Cause an Abnormal Urinary Betaine Loss Which is Associated with Elevations in Plasma Homocysteine. Cardiovascular Drugs and Therapy, 2009, 23, 395-401.	1.3	21
98	Plasma and urine betaine and dimethylglycine variation in healthy young male subjects. Clinical Biochemistry, 2009, 42, 706-712.	0.8	17
99	A patient with pseudo-Addison's disease and falsely elevated thyroxine due to interference in serum cortisol and free thyroxine immunoassays by two different mechanisms. Annals of Clinical Biochemistry, 2009, 46, 172-175.	0.8	19
100	Dietary and supplementary betaine: Effects on betaine and homocysteine concentrations in males. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 767-773.	1.1	43
101	N-3 polyunsaturated fatty acids and statins in heart failure. Lancet, The, 2009, 373, 379-380.	6.3	1
102	Spectrum of MECP2 mutations in New Zealand Rett syndrome patients. New Zealand Medical Journal, 2009, 122, 21-8.	0.5	2
103	Coenzyme Q10; an adjunctive therapy for congestive heart failure?. New Zealand Medical Journal, 2009, 122, 74-9.	0.5	19
104	Response to Narasimhan and Clausen's letter on heterophile antibodies and troponin results. New Zealand Medical Journal, 2009, 122, 121-2.	0.5	0
105	Comparison of the Mayo Clinic Quadratic Equation with the Modification of Diet in Renal Disease equation and radionuclide glomerular filtration rate in a clinical setting. Nephrology, 2008, 13, 684-688.	0.7	7
106	Differential identification of PTâ€VWD from type 2B VWD and GP1BA nomenclature issues response to Othman. British Journal of Haematology, 2008, 142, 314-315.	1.2	8
107	Coenzyme Q10. Journal of the American College of Cardiology, 2008, 52, 1435-1441.	1.2	184
108	Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa. Atherosclerosis, 2008, 196, 659-666.	0.4	81

#	Article	IF	Citations
109	Intermittent severe, symptomatic hyponatraemia due to the nephrogenic syndrome of inappropriate antidiuresis. Annals of Clinical Biochemistry, 2008, 45, 520-523.	0.8	22
110	Uncertainty of sweat chloride testing: does the right hand know what the left hand is doing?. Annals of Clinical Biochemistry, 2008, 45, 535-538.	0.8	11
111	Three cases of congenital adrenal hypoplasia with novel mutations in the (NROB1) DAX-1 gene. Annals of Clinical Biochemistry, 2008, 45, 606-609.	0.8	7
112	Revised national guidelines for analysis of CSF for bilirubin in suspected SAH. Annals of Clinical Biochemistry, 2008, 45, 617-618.	0.8	1
113	Effect of atorvastatin on plasma levels of asymmetric dimethylarginine in patients with nonâ€ischaemic heart failure. European Journal of Heart Failure, 2008, 10, 463-466.	2.9	26
114	Pseudo-hypertriglyceridaemia: a measurement artefact due to glycerol kinase deficiency. Postgraduate Medical Journal, 2008, 84, 552-554.	0.9	11
115	Rosuvastatin in Older Patients with Systolic Heart Failure. New England Journal of Medicine, 2008, 358, 1301-1301.	13.9	8
116	Trinucleotide repeat variants in the promoter of the thiopurine S-methyltransferase gene of patients exhibiting ultra-high enzyme activity. Pharmacogenetics and Genomics, 2008, 18, 434-438.	0.7	40
117	Dietary and supplementary betaine: acute effects on plasma betaine and homocysteine concentrations under standard and postmethionine load conditions in healthy male subjects. American Journal of Clinical Nutrition, 2008, 87, 577-585.	2.2	63
118	Suggested actions from the Melbourne HVP Information Seminar. Nature Precedings, 2008, , .	0.1	0
119	Suggested actions from the Melbourne HVP Information Seminar. Nature Precedings, 2008, , .	0.1	0
120	Cystatin C--a paradigm of evidence based laboratory medicine. Clinical Biochemist Reviews, 2008, 29, 47-62.	3.3	73
121	Coenzyme Q10: is there a clinical role and a case for measurement?. Clinical Biochemist Reviews, 2008, 29, 71-82.	3.3	77
122	Prospective validation of cerebrospinal fluid bilirubin in suspected subarachnoid haemorrhage. Annals of Clinical Biochemistry, 2007, 44, 140-144.	0.8	16
123	Quartz renal calculi: were we being led up the garden path?. Annals of Clinical Biochemistry, 2007, 44, 312-314.	0.8	0
124	Detection of Factor VIII Gene Mutations by High-Resolution Melting Analysis. Clinical Chemistry, 2007, 53, 2211-2214.	1.5	41
125	Novel Mutation (c.G1124A) in Exon 9 of the APOB Gene Causes Aberrant Splicing and Familial Hypobetalipoproteinemia. Clinical Chemistry, 2007, 53, 1165-1167.	1.5	2
126	Plasma Total Coenzyme Q9 (CoQ9) in the New Zealand Population: Reference Interval and Biological Variation. Clinical Chemistry, 2007, 53, 802-803.	1.5	13

#	Article	IF	Citations
127	Acquired dysfibrinogenemia caused by monoclonal production of immunoglobulin Â light chain. Haematologica, 2007, 92, e111-e117.	1.7	29
128	Novel fibrinogen AÎ± chain mutation associated with afibrinogenaemia. Pathology, 2007, 39, 519-520.	0.3	1
129	Concentration response to the coenzyme Q10 supplement Q-Gel in human volunteers. Nutrition Research, 2007, 27, 307-312.	1.3	11
130	Lungfish albumin is more similar to tetrapod than to teleost albumins: Purification and characterisation of albumin from the Australian lungfish, Neoceratodus forsteri. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 2007, 147, 428-437.	0.7	21
131	Autosomal recessive hypercholesterolaemia: Discrimination of ARH protein and LDLR function in the homozygous FH phenotype. Clinica Chimica Acta, 2007, 378, 33-37.	0.5	11
132	Double complex mutations involvingF8andFUNDC2caused by distinct break-induced replication. Human Mutation, 2007, 28, 1198-1206.	1.1	57
133	Inter- and intra-individual variations in normal urinary glycine betaine excretion. Clinical Biochemistry, 2007, 40, 447-453.	0.8	13
134	The molecular aetiology of haemophilia A in a New Zealand patient group. Haemophilia, 2007, 13, 420-427.	1.0	14
135	Differential identification of a rare form of platelet-type (pseudo-) von Willebrand disease (VWD) from Type 2B VWD using a simplified ristocetin-induced-platelet-agglutination mixing assay and confirmed by genetic analysis. British Journal of Haematology, 2007, 139, 623-626.	1.2	40
136	Dimethylthetin treatment causes diffuse alveolar lung damage: A pilot study in a sheep model of Continuous Ambulatory Peritoneal Dialysis (CAPD). Experimental and Toxicologic Pathology, 2007, 58, 285-290.	2.1	1
137	Effect of Coenzyme Q10 Supplementation on Simvastatin-Induced Myalgia. American Journal of Cardiology, 2007, 100, 1400-1403.	0.7	172
138	Effects of orange juice and proline betaine on glycine betaine and homocysteine in healthy male subjects. European Journal of Nutrition, 2007, 46, 446-452.	1.8	52
139	An abnormal urinary excretion of glycine betaine may persist for years. Clinical Biochemistry, 2007, 40, 798-801.	0.8	12
140	Sex differences in the control of plasma concentrations and urinary excretion of glycine betaine in patients attending a lipid disorders clinic. Clinical Biochemistry, 2007, 40, 1225-1231.	0.8	20
141	Novel human pathological mutations. Gene symbol: APOB. Disease: normotriglyceridemic hypobetalipoproteinemia. Human Genetics, 2007, 121, 645-6.	1.8	4
142	A simple gene test for lactose intolerance/adult hypolactasia. New Zealand Medical Journal, 2007, 120, U2817.	0.5	0
143	Mutant Fibrinogen Cleared from the Endoplasmic Reticulum via Endoplasmic Reticulum-Associated Protein Degradation and Autophagy. American Journal of Pathology, 2006, 168, 1299-1308.	1.9	103
144	Fibrinogen Darlinghurst: Hypofibrinogenaemia caused by a W253G mutation in the gamma chain in a patient with both bleeding and thrombotic complications. Thrombosis and Haemostasis, 2006, 96, 685-687.	1.8	8

#	Article	IF	Citations
145	Mysterious waxy deposit in urine Part 1. Pathology, 2006, 38, 449-450.	0.3	0
146	Chronic kidney disease and automatic reporting of estimated glomerular filtration rate. Medical Journal of Australia, 2006, 184, 41-43.	0.8	17
147	Sweat testing for cystic fibrosis: A review of New Zealand laboratories. Journal of Paediatrics and Child Health, 2006, 42, 160-164.	0.4	18
148	Thyroid hormone resistance: the role of mutational analysis. Internal Medicine Journal, 2006, 36, 738-741.	0.5	8
149	An intronic mutation within FGB (IVS1+2076 ag) is associated with afibrinogenemia and recurrent transient ischemic attacks. Journal of Thrombosis and Haemostasis, 2006, 4, 471-472.	1.9	18
150	A highly informative, multiplexed assay for the indirect detection of hemophilia A using five-linked microsatellites. Journal of Thrombosis and Haemostasis, 2006, 4, 587-590.	1.9	19
151	Comparison of two prediction equations with radionuclide glomerular filtration rate: validation in routine use. Annals of Clinical Biochemistry, 2006, 43, 309-313.	0.8	21
152	Dual porphyria with mutations in both the UROD and HMBS genes. Annals of Clinical Biochemistry, 2006, 43, 80-82.	0.8	18
153	Urinary VMA, dopamine and the likelihood of neuroblastoma: a preferred way of reporting laboratory results?. Annals of Clinical Biochemistry, 2006, 43, 300-305.	0.8	4
154	Fibrinogen Montreal: a novel missense mutation (Aa D496N) associated with hypofibrinogenaemia. Thrombosis and Haemostasis, 2006, 96, 231-2.	1.8	4
155	Hypofibrinogenaemia associated with common gamma82Ala-->Gly mutation is not mediated by altered mRNA splicing. Thrombosis and Haemostasis, 2006, 96, 535-7.	1.8	2
156	Autosomal recessive adult-onset hypophosphatasia. Pathology, 2005, 37, 563-565.	0.3	1
157	Plasma fluorescence scanning did not detect latent variegate porphyria in nine patients with non-p.R59W mutations. Pathology, 2005, 37, 324-326.	0.3	1
158	Vitamin D receptor genotypes influence the success of calcitriol therapy for recurrent vertebral fracture in osteoporosis. Pharmacogenetics and Genomics, 2005, 15, 127-135.	0.7	36
159	The betaine content of New Zealand foods and estimated intake in the New Zealand diet. Journal of Food Composition and Analysis, 2005, 18, 473-485.	1.9	69
160	Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. Internal Medicine Journal, 2005, 35, 580-585.	0.5	61
161	Novel sequence insertion in a Maori patient with transfusion-dependent beta-thalassaemia. British Journal of Haematology, 2005, 131, 400-402.	1.2	8
162	Mental retardation and ataxia due to normotriglyceridemic hypobetalipoproteinemia. Annals of Neurology, 2005, 58, 160-163.	2.8	13

#	Article	IF	Citations
163	Low Density Lipoprotein - Receptor (LDL-R) Gene Mutations among Filipinos with Familial Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis, 2005, 12, 276-283.	0.9	25
164	Familial hypodysfibrinogenaemia associated with second occurrence of Î³326 Cysâ†'Tyr mutation. Thrombosis and Haemostasis, 2005, 93, 612-613.	1.8	11
165	Biological Variation of Coenzyme Q10. Clinical Chemistry, 2005, 51, 455-457.	1.5	36
166	Use of Fully Denaturing HPLC for UGT1A1 Genotyping in Gilbert Syndrome. Clinical Chemistry, 2005, 51, 2183-2185.	1.5	12
167	Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis, 2005, 179, 201-206.	0.4	90
168	Hb Taradale [Î²82(EF6)Lysâ†'Arg]: A Novel Mutation at a 2,3-Diphosphoglycerate Binding Site. Hemoglobin, 2005, 29, 281-284.	0.4	2
169	Homocysteine, glycine betaine, and N,N-dimethylglycine in patients attending a lipid clinic. Metabolism: Clinical and Experimental, 2005, 54, 1-14.	1.5	55
170	The sialic acid content of fibrinogen decreases during pregnancy and increases in response to fibrate therapy. Thrombosis Research, 2005, 115, 293-299.	0.8	19
171	Hb riccarton [alpha51(CE9)Gly-->Ser]: a variant arising from a novel mutation in the alpha1 gene. Hemoglobin, 2005, 29, 61-4.	0.4	0
172	Effect of volcanic gas exposure on urine, blood, and serum chemistry. New Zealand Medical Journal, 2005, 118, U1319.	0.5	2
173	Recurrent myoglobinuria due to carnitine palmitoyltransferase II deficiency: clinical, biochemical, and genetic features of adult-onset cases. New Zealand Medical Journal, 2005, 118, U1320.	0.5	6
174	Measurement of thiopurine methyl transferase activity guides dose-initiation and prevents toxicity from azathioprine. New Zealand Medical Journal, 2005, 118, U1324.	0.5	17
175	Clinical indications for the investigation of porphyria: case examples and evolving laboratory approaches to its diagnosis in New Zealand. New Zealand Medical Journal, 2005, 118, U1658.	0.5	1
176	Automated Measurement of Cerebrospinal Fluid Bilirubin in Suspected Subarachnoid Hemorrhage. Clinical Chemistry, 2004, 50, 1854-1856.	1.5	10
177	Hereditary pancreatitis in a family of Aboriginal descent. Journal of Paediatrics and Child Health, 2004, 40, 487-489.	0.4	8
178	Fibrinogen Mannheim II: a novel gamma307 HisTyr substitution in the gammaD domain causes hypofibrinogenemia. Journal of Thrombosis and Haemostasis, 2004, 2, 2194-2199.	1.9	15
179	Trigonelline is not responsible for the acute increase in plasma homocysteine following ingestion of instant coffee. European Journal of Clinical Nutrition, 2004, 58, 1253-1256.	1.3	12
180	Elevated trace element output in urine following acute volcanic gas exposure. Journal of Volcanology and Geothermal Research, 2004, 134, 139-148.	0.8	24

#	Article	IF	Citations
181	A nuclear-magnetic-resonance-based assay for betaineâ€“homocysteine methyltransferase activity. Analytical Biochemistry, 2004, 330, 199-205.	1.1	17
182	Dimethylglycine supplementation does not affect plasma homocysteine concentrations in pre-dialysis chronic renal failure patients. Clinical Biochemistry, 2004, 37, 974-976.	0.8	12
183	Hypofibrinogenaemia associated with a novel heterozygous Î³289 Alaâ†'Val substitution (fibrinogen) Tj ETQq1 1 0.784314 rgBT /Over	1.8	8
184	Betaine analogues alter homocysteine metabolism in rats. International Journal of Biochemistry and Cell Biology, 2004, 36, 870-880.	1.2	32
185	The bioavailability of coenzyme Q10 supplements available in New Zealand differs markedly. New Zealand Medical Journal, 2004, 117, U1108.	0.5	17
186	Novel AÎ± chain truncation (fibrinogen Perth) resulting in low expression and impaired fibrinogen polymerization. Journal of Thrombosis and Haemostasis, 2003, 1, 1245-1250.	1.9	18
187	Plasma adiponectin in overweight, nondiabetic individuals with or without insulin resistance. Diabetes, Obesity and Metabolism, 2003, 5, 349-353.	2.2	88
188	Glycine betaine and glycine betaine analogues in common foods. Food Chemistry, 2003, 83, 197-204.	4.2	194
189	Familial hypofibrinogenaemia associated with heterozygous substitution of a conserved arginine residue; BÎ²255 Argâ†'His (Fibrinogen Merivale). Biochimica Et Biophysica Acta - Proteins and Proteomics, 2003, 1645, 146-151.	1.1	19
190	Haemoglobin Marseille-Long Island and interpretation of HbA1c: which HbA1c result is the "right answer"?. Postgraduate Medical Journal, 2003, 79, 174-175.	0.9	4
191	Contamination of Qiagen DNA Extraction Kits with Legionella DNA. Journal of Clinical Microbiology, 2003, 41, 3452-3453.	1.8	55
192	Fibrinogen BÎ²2 polymorphisms do not directly contribute to an altered in vitro clot structure in humans. Thrombosis and Haemostasis, 2003, 90, 1021-1028.	1.8	27
193	6-thioguanine nucleotides and thiopurine methyltransferase activity: important factors determining response to treatment and incidence of adverse effects from azathioprine and 6-MP. New Zealand Medical Journal, 2003, 116, U531.	0.5	1
194	Using serum albumin to infer vertebrate phylogenies. Applied Bioinformatics, 2003, 2, S97-107.	1.7	7
195	Fibrinogen Hillsborough: a novel Î³Gly309Asp dysfibrinogen with impaired clotting. Blood, 2002, 99, 3597-3601.	0.6	11
196	Macro-alkaline phosphatase due to IgG Îº complex: demonstration with polyethylene glycol precipitation and immunofixation. Annals of Clinical Biochemistry, 2002, 39, 523-525.	0.8	7
197	Novel Fibrinogen Truncation with Deletion of BÎ²2 Chain Residues 440-461 causes Hypofibrinogenaemia. Thrombosis and Haemostasis, 2002, 88, 427-431.	1.8	19
198	Comparison of SSCP and DHPLC for the detection of LDLR mutations in a New Zealand cohort. Human Mutation, 2002, 19, 311-311.	1.1	37

#	Article	IF	Citations
199	Betaine supplementation decreases post-methionine hyperhomocysteinemia in chronic renal failure. Kidney International, 2002, 61, 1040-1046.	2.6	72
200	Novel fibrinogen Î³375 Argâ†'Trp mutation (fibrinogen aguadilla) causes hepatic endoplasmic reticulum storage and hypofibrinogenemia. Hepatology, 2002, 36, 652-658.	3.6	87
201	Four novel polymorphisms in the fibrinogen Aalpha gene. Thrombosis and Haemostasis, 2002, 87, 354-5.	1.8	0
202	Improved clinical management of retinoblastoma through gene testing. New Zealand Medical Journal, 2002, 115, 231-4.	0.5	2
203	Hypofibrinogenemia due to Novel 316 Asp â†' Tyr Substitution in the Fibrinogen BÎ² Chain. Thrombosis and Haemostasis, 2001, 85, 450-453.	1.8	25
204	Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations. Kidney International, 2001, 59, 2267-2272.	2.6	77
205	Influence of haemochromatosis gene mutations on treatment outcomes in patients with hepatitis C. Internal Medicine Journal, 2001, 31, 254-255.	0.5	3
206	Î³371 Thrâ†'Ile substitution in the fibrinogen Î³D domain causes hypofibrinogenaemia. BBA - Proteins and Proteomics, 2001, 1550, 183-188.	2.1	14
207	Genetic and Immunological Characterization of Fibrinogen Inclusion Bodies in Patients with Hepatic Fibrinogen Storage and Liver Disease. Annals of the New York Academy of Sciences, 2001, 936, 522-525.	1.8	25
208	Identification and Characterization of Five New Fibrinogen Gene Polymorphisms. Annals of the New York Academy of Sciences, 2001, 936, 536-541.	1.8	14
209	Molecular Mechanisms of Hypoâ€•and Afibrinogenemia. Annals of the New York Academy of Sciences, 2001, 936, 91-100.	1.8	34
210	Hypofibrinogenemia due to novel 316 Asp --> Tyr substitution in the fibrinogen Bbeta chain. Thrombosis and Haemostasis, 2001, 85, 450-3.	1.8	2
211	Implementation of evidence based cardiovascular risk treatments by general practitioners. New Zealand Medical Journal, 2001, 114, 260-2.	0.5	0
212	Is thiamine deficiency in elderly people related to age or co-morbidity?. Age and Ageing, 2000, 29, 111-116.	0.7	48
213	A Novel 5â€² (40^41insA) Mutation in a Patient with Numerous Manifestations of Cowden Disease. Journal of Investigative Dermatology, 2000, 114, 597-598.	0.3	6
214	Defective fibrinogen polymerization associated with a novel Î³279Alaâ†'Asp mutation. British Journal of Haematology, 2000, 108, 236-240.	1.2	7
215	Three truncated forms of serum albumin associated with pancreatic pseudocyst. BBA - Proteins and Proteomics, 2000, 1481, 337-343.	2.1	16
216	Effect of nonsense mutations on PTEN mRNA stability. Human Genetics, 2000, 107, 24-27.	1.8	2

#	Article	IF	Citations
217	Hypofibrinogenemia in an individual with 2 coding (Î³82 Aâ†'G and BÎ²235 Pâ†'L) and 2 noncoding mutations. Blood, 2000, 95, 1709-1713.	0.6	48
218	Homozygous truncation of the fibrinogen AÎ± chain within the coiled coil causes congenital afibrinogenemia. Blood, 2000, 96, 773-775.	0.6	36
219	Correction for Stott et al.: Simple Multiplex PCR for the Simultaneous Detection of the C282Y and H63D Hemochromatosis (HFE) Gene Mutations. Clinical Chemistry, 2000, 46, 308-309.	1.5	1
220	Fibrinogen Brescia. American Journal of Pathology, 2000, 157, 189-196.	1.9	106
221	Effect of nonsense mutations on PTEN mRNA stability. Human Genetics, 2000, 107, 24-27.	1.8	7
222	Homozygous truncation of the fibrinogen AÎ± chain within the coiled coil causes congenital afibrinogenemia. Blood, 2000, 96, 773-775.	0.6	13
223	Hypofibrinogenemia in an individual with 2 coding (gamma82 A-->G and Bbeta235 P-->L) and 2 noncoding mutations. Blood, 2000, 95, 1709-13.	0.6	11
224	Homozygous truncation of the fibrinogen A alpha chain within the coiled coil causes congenital afibrinogenemia. Blood, 2000, 96, 773-5.	0.6	1
225	Hypofibrinogenaemia with compound heterozygosity for two gamma chain mutations - gamma 82 Ala-->Gly and an intron two GT-->AT splice site mutation. Thrombosis and Haemostasis, 2000, 84, 449-52.	1.8	5
226	The prevalence of viral hepatitis (HAV, HBV and HCV) in the Christchurch community. New Zealand Medical Journal, 2000, 113, 394-6.	0.5	6
227	High density lipoprotein (HDL), and not albumin, is the major palmitate binding protein in New Zealand long-finned (Anguilla dieffenbachii) and short-finned eel (Anguilla australis schmidtii) plasma. BBA - Proteins and Proteomics, 1999, 1429, 467-475.	2.1	24
228	Albumin Banks Peninsula: a new termination variant characterised by electrospray mass spectrometry. BBA - Proteins and Proteomics, 1999, 1433, 321-326.	2.1	15
229	Catalytic parameters for the hydrolysis of butyrylthiocholine by human serum butyrylcholinesterase variants. Chemico-Biological Interactions, 1999, 119-120, 165-171.	1.7	4
230	The characterization of ovine genes for atrial, brain, and C-type natriuretic peptides. Domestic Animal Endocrinology, 1999, 16, 115-121.	0.8	18
231	The Antarctic toothfish (Dissostichus mawsoni) lacks plasma albumin and utilises high density lipoprotein as its major palmitate binding protein. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 1999, 124, 147-155.	0.7	25
232	Haemochromatosis gene mutations Cys282Tyr and His63Asp are not increased in Type 2 diabetic patients compared with the Canterbury (New Zealand) general population. Diabetes Research and Clinical Practice, 1999, 43, 199-203.	1.1	15
233	Simple multiplex PCR for the simultaneous detection of the C282Y and H63D hemochromatosis (HFE) gene mutations. Clinical Chemistry, 1999, 45, 426-8.	1.5	8
234	The Stent report, one year on. Christchurch Hospital's Medical Specialists Association. New Zealand Medical Journal, 1999, 112, 278-9.	0.5	0

#	Article	IF	Citations
235	Albumin Church Bay: 560 Lysâ†'Glu a new mutation detected by electrospray ionisation mass spectrometry. BBA - Proteins and Proteomics, 1998, 1382, 305-310.	2.1	10
236	Electrospray ionization mass spectrometry identification of fibrinogen Banks Peninsula (Î³280Tyrâ†'Cys): a new variant with defective polymerization. British Journal of Haematology, 1998, 101, 24-31.	1.2	21
237	The Albumins of Chinook Salmon (Oncorhynchus tshawytscha) and Brown Trout (Salmo trutta) Appear to Lack a Propeptide. Archives of Biochemistry and Biophysics, 1998, 350, 239-244.	1.4	27
238	The significance of haemochromatosis gene mutations in the general population: implications for screening. Gut, 1998, 43, 830-836.	6.1	215
239	Oligosaccharide Configuration of Fibrinogen Kaiserslautern: Electrospray Ionisation Analysis of Intact Î³ Chains. Thrombosis and Haemostasis, 1998, 80, 263-265.	1.8	12
240	Oligosaccharide configuration of fibrinogen Kaiserslautern: electrospray ionisation analysis of intact gamma chains. Thrombosis and Haemostasis, 1998, 80, 263-5.	1.8	2
241	Plasma androsterone/epiandrosterone sulfates as markers of 5Î±-reductase activity: Effect of finasteride in normal men. Steroids, 1997, 62, 632-635.	0.8	14
242	Rapid Detection of the Fibrinogen AÎ±16Argâ†'His Mutation. Clinical Chemistry, 1997, 43, 2184-2186.	1.5	3
243	The response to treatment of subclinical thiamine deficiency in the elderly. American Journal of Clinical Nutrition, 1997, 66, 925-928.	2.2	52
244	Endoproteases other than furin have a role in hepatic proprotein processing. IUBMB Life, 1997, 42, 1131-1142.	1.5	1
245	Fibrinogen Otago: a major Î± chain truncation associated with severe hypofibrinogenaemia and recurrent miscarriage. British Journal of Haematology, 1997, 98, 632-639.	1.2	66
246	Fibrinogen Kaiserslautern (ÃŽÂ³ 380 Lys to Asn): a new glycosylated fibrinogen variant with delayed polymerization. British Journal of Haematology, 1997, 99, 563-569.	1.2	17
247	Rapid detection of the fibrinogen A alpha 16Arg --> His mutation. Clinical Chemistry, 1997, 43, 2184-6.	1.5	2
248	Molecular analysis of HLA-H gene mutations in New Zealand patients with haemochromatosis. New Zealand Medical Journal, 1997, 110, 429-32.	0.5	6
249	Electrospray ionisation mass spectrometry facilitates detection of fibrinogen (Bbeta 14 Arg --> Cys) mutation in a family with thrombosis. Thrombosis and Haemostasis, 1997, 78, 1484-7.	1.8	1
250	Yeast aspartic protease 3 (Yap3) prefers substrates with basic residues in the P2, P1and P2â€² positions. FEBS Letters, 1996, 383, 67-71.	1.3	23
251	The specificity of the neuroendocrine convertase PC3 is determined by residues NH2- and COOH-terminal to the cleavage site. IUBMB Life, 1996, 39, 1167-1176.	1.5	1
252	Expression of humanKrev-1 gene in lungs of transgenic mice and subsequent reduction in multiplicity of ethyl carbamate-induced lung adenomas. , 1996, 17, 84-91.		8

#	Article	IF	Citations
253	Fibrinogen Lincoln: a new truncated ? chain variant with delayed clotting. British Journal of Haematology, 1996, 93, 177-184.	1.2	35
254	Characterization of lipoproteins containing a truncated form of apolipoprotein B, apolipoprotein B32. Lipids and Lipid Metabolism, 1995, 1258, 49-56.	2.6	1
255	Superoxide dismutase (glu100 â†' gly) in a family with inherited motor neuron disease: detection of mutant superoxide dismutase activity and the presence of heterodimers. Neuroscience Letters, 1995, 189, 143-146.	1.0	22
256	Aberrant hepatic processing causes removal of activation peptide and primary polymerisation site from fibrinogen Canterbury (A alpha 20 Val --> Asp).. Journal of Clinical Investigation, 1995, 96, 2854-2858.	3.9	58
257	Improved detection of Chlamydia trachomatis in endocervical samples by using a new polymerase chain reaction assay. New Zealand Medical Journal, 1995, 108, 292-4.	0.5	3
258	Huntington's disease: diagnosis by amplification of the CAG repeat. New Zealand Medical Journal, 1995, 108, 78-80.	0.5	1
259	Thyroxine binding by human transthyretin variants: mutations at position 119, but not position 54, increase thyroxine binding affinity. Journal of Clinical Endocrinology and Metabolism, 1994, 78, 459-462.	1.8	11
260	Investigation of subjects with abnormal iron studies: role of the hepatic iron index. New Zealand Medical Journal, 1994, 107, 504-7.	0.5	6
261	Correlation between Genotype and Phenotype in Patients with Cystic Fibrosis. New England Journal of Medicine, 1993, 329, 1308-1313.	13.9	567
262	Concurrent hepatitis B and C infection treated successfully with alpha interferon. Australian and New Zealand Journal of Medicine, 1993, 23, 411-412.	0.5	11
263	Posttranslational Modification of Î²141 LEU Associated with the Î²75(E19)Leuâ†'pro Mutation in HB Atlanta. Hemoglobin, 1993, 17, 1-7.	0.4	16
264	Lead exposure during recreational use of small bore rifle ranges. New Zealand Medical Journal, 1993, 106, 422-4.	0.5	9
265	Selenium and Glutathione Peroxidase Levels in Premature Infants in a Low Selenium Community (Christchurch, New Zealand). Pediatric Research, 1992, 32, 189-194.	1.1	46
266	A Novel Variant of Transthyretin (Prealbumin), Thr¹¹⁹to Met, Associated with Increased Thyroxine Binding. Thyroid, 1992, 2, 21-26.	2.4	22
267	Apolipoprotein B-32: a new truncated mutant of human apolipoprotein B capable of forming particles in the low density lipoprotein range. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1992, 1138, 290-296.	1.8	16
268	A competitive ELISA for lipoprotein(a). Clinica Chimica Acta, 1992, 205, 213-222.	0.5	8
269	Fasting plasma lipid measurements following cisplatin chemotherapy in patients with germ cell tumors.. Journal of Clinical Oncology, 1992, 10, 1609-1614.	0.8	27
270	The predicted proteinase furin is not the hepatic proalbumin convertase. BBA - Proteins and Proteomics, 1992, 1159, 9-12.	2.1	2

#	Article	IF	Citations
271	A family with haemolytic anaemia and three Î²-globins: the deletion in haemoglobin Atlanta-Coventry (Î²75) Tj ETQq1 1 0.784314 rgBT / 93-98.	1.2	5
272	Î²141 Leu is not deleted in the unstable haemoglobin Atlanta-Coventry but is replaced by a novel amino acid of mass 129 daltons. British Journal of Haematology, 1992, 81, 99-103.	1.2	30
273	Industrial blood lead levels in the South Island during 1988 and 1989: trends and follow up patterns. New Zealand Medical Journal, 1992, 105, 323-6.	0.5	0
274	Increase in selenium status of Christchurch adults associated with deregulation of the wheat market. New Zealand Medical Journal, 1992, 105, 466-8.	0.5	3
275	Selenium status of Christchurch infants and the effect of diet. New Zealand Medical Journal, 1992, 105, 139-42.	0.5	14
276	Effect of diet on posttransplant hyperlipidaemia. New Zealand Medical Journal, 1992, 105, 79-80.	0.5	8
277	A testing time for heart disease. New Zealand Medical Journal, 1992, 105, 258-60.	0.5	0
278	P1 variant antithrombins Glasgow (393 Arg to His) and Pescara (393 Arg to Pro) have increased heparin affinity and are resistant to catalytic cleavage by elastase Implications for the heparin activation mechanism. FEBS Letters, 1991, 280, 216-220.	1.3	15
279	Concurrence of hereditary spherocytosis and alpha thalassaemia. Australian and New Zealand Journal of Medicine, 1991, 21, 485-486.	0.5	5
280	Rapid detection and initial characterization of genetic variants of human serum albumin. Clinical Chemistry, 1991, 37, 1221-1224.	1.5	9
281	Functional antithrombin-III variant (41 proâ†'leu) identified by liquid secondary ion mass spectrometry. Pathology, 1991, 23, 1-4.	0.3	7
282	Molecular screening of cystic fibrosis patients. New Zealand Medical Journal, 1991, 104, 415-6.	0.5	0
283	Methylprednisolone in multiple sclerosis exacerbation: changes in CSF parameters. Australian and New Zealand Journal of Medicine, 1990, 20, 794-797.	0.5	7
284	Albumin Redhill (-1 Arg, 320 Ala----Thr): a glycoprotein variant of human serum albumin whose precursor has an aberrant signal peptidase cleavage site.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 26-30.	3.3	60
285	Hypermutability of CpG dinucleotides in the propeptide-encoding sequence of the human albumin gene.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 3909-3913.	3.3	46
286	Antithrombin Rouen-IV 24 Argâ†'Cys The amino-terminal contribution to heparin binding. FEBS Letters, 1990, 266, 163-166.	1.3	30
287	The use of laboratory data. New Zealand Medical Journal, 1990, 103, 515.	0.5	2
288	Diagnosis and the polymerase chain reaction. New Zealand Medical Journal, 1990, 103, 39-40.	0.5	0

#	Article	IF	Citations
289	Apolipoprotein E2-Dunedin (228 Arg replaced by Cys): an apolipoprotein E2 variant with normal receptor-binding activity. Journal of Lipid Research, 1990, 31, 535-43.	2.0	21
290	DNA analysis using polymerase chain reactions in the families of children with cystic fibrosis. New Zealand Medical Journal, 1990, 103, 216-7.	0.5	0
291	AST:ALT ratios. New Zealand Medical Journal, 1990, 103, 433.	0.5	0
292	Apolipoprotein E variation in patients with hyperlipidaemia: DNA and protein phenotyping. New Zealand Medical Journal, 1989, 102, 534-6.	0.5	0
293	Screening for plasma cholinesterase deficiency: an automated succinylcholine based assay. Clinical Biochemistry, 1988, 21, 159-162.	0.8	4
294	Characterisation of a slow component of normal human serum albumin. Clinica Chimica Acta, 1988, 176, 179-184.	0.5	22
295	New carbohydrate site in mutant antithrombin (7 Ileâ†'Asn) with decreased heparin affinity. FEBS Letters, 1988, 237, 118-122.	1.3	67
296	Cleavage and inactivation of alpha 1-antitrypsin by metalloproteinases released from neutrophils.. Journal of Clinical Investigation, 1988, 82, 706-711.	3.9	95
297	The quality of performance of the fructosamine test. New Zealand Medical Journal, 1988, 101, 606-8.	0.5	2
298	Multiple sclerosis: problems in the evaluation of intrathecal IgG synthesis. New Zealand Medical Journal, 1988, 101, 790-2.	0.5	0
299	Detection of protein binding abnormalities in euthyroid hyperthyroxinemia. Clinical Chemistry, 1988, 34, 1745-8.	1.5	0
300	Physiological variant of antithrombin-III lacks carbohydrate sidechain at Asn 135. FEBS Letters, 1987, 219, 431-436.	1.3	110
301	Kinetic Studies on the Interaction of Î±₁-Proteinase Inhibitor (Pittsburgh) with Trypsin-Like Serine Proteinases. Biological Chemistry Hoppe-Seyler, 1986, 367, 853-860.	1.4	36
302	Plasma cholinesterase phenotyping with use of visible-region spectrophotometry. Clinical Chemistry, 1986, 32, 194-7.	1.5	1
303	A case of partial deficiency of alpha 1-antichymotrypsin. Clinical Chemistry, 1985, 31, 1739-40.	1.5	1
304	Isolation and properties of recombinant DNA produced variants of human alpha 1-proteinase inhibitor. Journal of Biological Chemistry, 1985, 260, 4384-9.	1.6	102
305	Structural and functional characterization of the abnormal Z Î±1 -antitrypsin isolated from human liver. FEBS Letters, 1984, 177, 179-183.	1.3	72
306	A new succinylcholine-based assay of plasma cholinesterase. Clinical Chemistry, 1984, 30, 192-5.	1.5	4

#	Article	IF	Citations
307	Is there a role for routine estimations of plasma magnesium?. Clinical Biochemistry, 1983, 16, 191-194.	0.8	6
308	Improved Ellman procedure for erythrocyte cholinesterase. Clinical Chemistry, 1983, 29, 365-8.	1.5	9
309	Suggested actions from the Melbourne HVP Information Seminar. Nature Precedings, 0, , .	0.1	1